Results 21 to 30 of about 93,808 (329)

Tocolysis with nifedipine versus atosiban and perinatal outcome: an individual participant data meta-analysis

open access: yesBMC Pregnancy and Childbirth, 2022
Background Worldwide, nifedipine and atosiban are the two most commonly used tocolytic agents for the treatment of threatened preterm birth. The aim of this study was to evaluate the effectiveness of nifedipine and atosiban in an individual participant ...
Tijn M. S. van Winden   +9 more
doaj   +1 more source

Effect of topical nifedipine in treatment of chronic anal fissure

open access: yesInternational Journal of Surgery Science, 2019
Chronic anal fissure is the most common cause of anal pain associated with internal anal sphincter hypertonia. Reduction of hypertonocity is a special treatment for fisssure healing.
D. Kc, Dr. Chinnabovi
semanticscholar   +1 more source

Therapy for nifedipine-induced gingival overgrowth by saireito in rats

open access: yesEuropean Journal of Medical Research, 2009
Objective A calcium antagonist, nifedipine, causes gingival overgrowth as a side effect. It has been confirmed that the Japanese traditional medicine, Saireito, inhibits the nifedipine-induced proliferation of gingival fibroblasts in vitro.
Hattori T   +5 more
doaj   +1 more source

DIHYDROPYRIDINE CALCIUM ANTAGONISTS. POSITION OF NIFEDIPINE IN MODERN CARDIOLOGY PRACTICE

open access: yesРациональная фармакотерапия в кардиологии, 2016
Position of nifedipine in modern cardiology practice is highlighted. Nifedipine usage for arterial hypertension therapy , including combined one, stroke prevention, treatment of hypertensive crisis and ischemic heart disease is considered.
A. A. Garganeeva
doaj   +1 more source

Use of drug therapy in the management of symptomatic ureteric stones in hospitalized adults (SUSPEND), a multicentre, placebo-controlled, randomized trial of a calcium-channel blocker (nifedipine) and an α-blocker (tamsulosin) : study protocol for a randomized controlled trial [PDF]

open access: yes, 2014
Peer reviewedPublisher ...
Anson, Ken   +12 more
core   +2 more sources

Development of a UV-Stabilized Topical Formulation of Nifedipine for the Treatment of Raynaud Phenomenon and Chilblains

open access: yesPharmaceutics, 2019
Raynaud’s Phenomenon is a vascular affliction resulting in pain and blanching of the skin caused by excessive and prolonged constriction of arterioles, usually due to cold exposure.
Ellen K. Wasan   +10 more
doaj   +1 more source

Mechanisms of Nifedipine-Downregulated CD40L/sCD40L Signaling in Collagen Stimulated Human Platelets. [PDF]

open access: yesPLoS ONE, 2015
The platelet-derived soluble CD40L (sCD40L) release plays a critical role in the development of atherosclerosis. Nifedipine, a dihydropyridine-based L-type calcium channel blocker (CCB), has been reported to have an anti-atherosclerotic effect beyond its
Tso-Hsiao Chen   +3 more
doaj   +1 more source

Atosiban in the management of preterm labour [PDF]

open access: yes, 2011
Peer reviewedPublisher ...
Bhattacharya, Sohinee   +3 more
core   +3 more sources

Epigallocatechin gallate enhances treatment efficacy of oral nifedipine against pregnancy‐induced severe pre‐eclampsia: A double‐blind, randomized and placebo‐controlled clinical study

open access: yesJournal of Clinical Pharmacy and Therapeutics, 2018
Oral nifedipine is commonly used to treat pre‐eclampsia, one of the most severe complications during pregnancy, but its clinical efficacy is less than ideal. Epigallocatechin gallate (EGCG), a natural compound from green tea, could benefit cardiovascular
Dandan Shi, Junjun Guo, L. Zhou, N. Wang
semanticscholar   +1 more source

Ontogeny of purinergic receptor-regulated Ca2+ signaling in mouse cortical collecting duct epithelium [PDF]

open access: yes, 2002
Changes in ATP-induced increase in {[}Ca2+], during collecting duct ontogeny were studied in primary monolayer cultures of mouse ureteric bud (UB) and cortical collecting duct (CCD) cells by Fura-PE3 fluorescence ratio imaging.
Borscheid, R.   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy